Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of ...

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.33 per share a year ago. These figures are ...

TXG BLFS NAGE AZTA ADPT MLAB Company Name 10x Genomics, Inc. BioLife Solutions, Inc. Niagen Bioscience, Inc. Azenta, Inc. Adaptive Biotechnologies Corporation Mesa Laboratories, Inc. Sector Health ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

10x Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

TXG Finanicals Stock Screener Earnings Calendar Sectors Nasdaq Search Ticker | TXG U.S.: Nasdaq 10x Genomics Inc. + Watchlist Alert TXG US After Hours Last Updated: Apr 25, 2025 6:27 p.m. EDT ...